Orthodontists who print their own clear aligners may be spending more than they think once a case stretches beyond roughly six months of treatment. A new survey-based economic analysis of US orthodontic practices finds that in-house aligner fabrication is cost-efficient only up to a fairly narrow window: once a case requires approximately 22 to 26 aligner pairs, commercially manufactured aligners become the cheaper option, assuming a commercial fee of $1,500 per case. The threshold analysis, published as open access research in the journal Digital and Aligner Orthodontics, combined a 30-item electronic survey of practicing orthodontists with an economic model of fixed and variable production costs.
The study team, led by Bob Kumra, Neal D. Kravitz, Nikhilesh R. Vaid and T. Scott Jenkins, distributed the survey through professional networks and electronic mailing lists using SurveyMonkey. Because the invitation circulated through overlapping networks, the researchers could not determine how many orthodontists received it and therefore could not calculate a precise response rate. Data collection continued until roughly 200 usable responses were gathered. After cleaning, 56 responses were excluded: 36 came from practitioners who owned three-dimensional printers but used them only for retainer fabrication, ten lacked sufficient identifying information, six practiced outside the United States, three originated from the same office, and one came from a commercial aligner laboratory owner whose production volumes were not representative of practice-based workflows. That left 201 surveys in the final analysis.
The respondents painted a picture of modest, focused in-house operations rather than full-scale manufacturing plants. Most practices were single-location (43.5 percent) or two-location (34.5 percent), and nearly all reported current use of in-house aligners, at 92.4 percent. Existing office space was most often retrofitted to accommodate production (65.5 percent), and most laboratories occupied 200 square feet or less (64.4 percent). Laboratory build-out costs, excluding equipment, most commonly ranged from $2,500 to $10,000. Most practices ran one or two printers (65.6 percent), typically SprintRay or Formlabs systems, alongside one wash station and one curing unit, a single dedicated computer, and one technician.
Production volumes matched this compact footprint. Most practices initiated between 5 and 10 in-house aligner cases per month, and typical cases involved 5 to 15 aligner pairs, with about one-third of respondents reporting 5 pairs per case and another one-third reporting 10. Respondents commonly estimated that a technician could trim, polish and package roughly 6 to 8 aligner pairs per hour. uLab software dominated in-house design work, used by 76.5 percent of practices. Notably, most respondents viewed in-house fabrication as economically advantageous compared with commercial aligners (73.9 percent), most often citing faster turnaround times (77.9 percent) and cost savings (60.8 percent) — perceptions the economic model would go on to qualify.
To model the economics, the researchers treated commercial aligner therapy as a fixed per-case fee, set at $1,500, described as a mid-range negotiated fee consistent with commonly reported US pricing. In-house costs were modeled as fixed costs allocated per case plus variable costs that scale linearly with aligner quantity, expressed as C_IHA = F + cN, where F is fixed cost per case, c is variable cost per aligner pair and N is the number of pairs. An in-house pair consists of one maxillary and one mandibular aligner. Fixed costs included laboratory build-out, capital equipment, software subscriptions and operational overhead, amortized across monthly case volume as reported in the survey. A representative capital equipment investment of approximately $15,000 was incorporated, covering three-dimensional printers, wash and curing units, thermoforming equipment and a dedicated workstation.
The variable production cost per pair was estimated at $40 to $50, based on commonly reported manufacturing estimates from clinical workflows — including materials, thermoforming, trimming and technician labor — drawn from previously published reports and the authors’ internal laboratory experience. The break-even quantity was calculated as N* = (P − F)/c, where P is the per-case commercial fee. Sensitivity analyses varied commercial fees and fixed-cost allocation across clinically plausible ranges. Under the baseline $1,500 commercial fee, the model placed the cost-efficiency threshold at approximately 22 to 26 in-house aligner pairs, corresponding to roughly six months of aligner therapy. Below that point, in-house fabrication is cheaper; above it, the fixed commercial fee wins out.
The divergence stems from fundamentally different cost structures. In an in-house workflow, variable costs accrue with every additional pair printed, so total treatment cost climbs in an essentially straight line as aligner requirements rise. Commercial systems, by contrast, charge a largely fixed per-case fee that stays stable regardless of how many aligners a case consumes. Where those two lines cross lies the threshold. The authors argue this explains why survey respondents appear to use in-house fabrication in a way that matches its greatest economic advantage: typical cases of 5 to 15 pairs sit comfortably below the 22-to-26-pair crossover, suggesting orthodontists reserve in-house production for shorter treatments rather than attempting to replace commercial systems wholesale.
The implications for complex cases are less favorable for in-house workflows. Because the orthodontist effectively becomes the manufacturer, variable production costs scale with every refinement, and the authors note that in-house fabrication is unlikely to reach cost equivalence for more complex cases — or even for simple cases involving patients who insist on multiple refinements. The economic advantages of in-house production therefore appear more limited than previously suggested in the literature, with in-house fabrication more likely to approach cost equivalence than clear cost superiority as aligner requirements increase. The authors also point to hidden opportunity costs not captured in per-aligner estimates: in-house production commonly requires reallocating a trained clinical team member to oversee fabrication and may demand increased doctor oversight of laboratory workflows, quality control and troubleshooting.
What in-house fabrication does offer, the analysis suggests, is less about raw cost and more about control and flexibility: ownership of digital records and scan data, customized staging and refinements, same-day aligner fabrication and practice-specific branding. Some commercial systems retain control over intraoral scans and associated digital files, potentially limiting clinician autonomy and long-term access to patient records — concerns that have grown as aligner adoption expands. Clear aligner therapy now accounts for approximately 25 percent of patients in many US orthodontic practices, and one cited study indicates in-house fabrication is used by more than a quarter of US orthodontists, with adoption highest among practitioners aged 36 to 45 years. Meanwhile, commercial manufacturers have responded to in-house growth with subscription-based, pay-per-aligner programs reporting per-aligner costs of approximately $30 to $40 plus monthly service fees, models that may narrow the cost differential in low-aligner cases while preserving commercial efficiency in longer treatments.
The authors caution that several limitations shape these findings. The study relied on self-reported survey data, which may be subject to recall bias or estimation imprecision; in-house workflows vary across practices in ways that influence both fixed and variable costs; commercial pricing was modeled as a fixed per-case fee even though volume-based discounts differ among practices; and reported laboratory build-out costs may be conservative for larger practices, potentially shifting the threshold. Importantly, the analysis addressed economics only, not clinical outcomes, treatment efficiency or patient satisfaction, any of which may independently influence workflow choice. Although one cited study reported comparable accuracy between in-house and commercially manufactured aligners, its generalizability remains uncertain, particularly for complex cases. Within those bounds, the practical takeaway is that cost efficiency between the two production routes is driven primarily by anticipated aligner quantity and practice-specific economics rather than fabrication method alone — and identifying the clinically relevant threshold points can help orthodontists select the most appropriate workflow for each case.
Subject of Research: Cost-efficiency thresholds between in-house and commercially manufactured clear aligners in US orthodontic practice
Article Title: Comparison of cost efficiency between commercially manufactured and in-house aligners: a threshold analysis
Article References: Kumra, B., Kravitz, N. D., Vaid, N. R., & Jenkins, T. S. (2026). Comparison of cost efficiency between commercially manufactured and in-house aligners: a threshold analysis. Digital and Aligner Orthodontics, 1(1), Article 2. https://doi.org/10.1007/s44525-026-00004-6
Image Credits: AI Generated
DOI: 10.1007/s44525-026-00004-6
Keywords: clear aligners, in-house aligner fabrication, orthodontics, cost-efficiency threshold analysis, economic modeling, 3D printing, survey research, commercial aligner fees, practice management, digital dentistry, aligner quantity, United States
News Source: Denise Maddox. (October 29, 2026). In-House Aligners Save Money Only Below a 22–26 Pair Threshold. Scienmag.
